High expression of B7‑H2 or B7‑H3 is associated with poor prognosis in hepatocellular carcinoma

Zheng,Youshi; Liao,Naishun; Wu,Yuan; Gao,Ju; Li,Zhenli; Liu,Wenwen; Wang,Yingchao; Li,Ming; Li,Xiaolou; Chen,Li; Zhang,Wenmin; Zhao,Bixing

doi:10.3892/mmr.2019.10080

High expression of B7‑H2 or B7‑H3 is associated with poor prognosis in hepatocellular carcinoma

Authors:
- Youshi Zheng
- Naishun Liao
- Yuan Wu
- Ju Gao
- Zhenli Li
- Wenwen Liu
- Yingchao Wang
- Ming Li
- Xiaolou Li
- Li Chen
- Wenmin Zhang
- Bixing Zhao
View Affiliations

Affiliations: The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, Fujian 350025, P.R. China, Department of Pathology, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, Fujian 350122, P.R. China, Department of Anatomy and Embryology, The School of Basic Medical Sciences, Fujian Medical University, Fuzhou, Fujian 350108, P.R. China
Published online on: March 22, 2019 https://doi.org/10.3892/mmr.2019.10080
Pages: 4315-4325
Copyright: © Zheng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

B7 family members have been associated with the signaling transduction pathways underlying tumor immune evasion in hepatocellular carcinoma. In the present study, associations between the clinical characteristics of patients with hepatocellular carcinoma (HCC) and the expression of B7‑H2 and B7‑H3 were analyzed. A total of 63 formalin‑fixed and paraffin‑embedded HCC tissues were collected to be used as a tissue microarray. Following this, the association between B7‑H2/B7‑H3 and the prognosis of patients with HCC was analyzed using Pearson's χ2 test, the Kaplan‑Meier method and receiver operating characteristic curve analysis. The results demonstrated that the expression of B7‑H2 was significantly associated with recurrence (within 1 year) in patients with HCC (P<0.01), and that the expression of B7‑H3 was associated with recurrence (within 1 year), metastasis and 2‑year overall survival rate in patients with HCC (P<0.01, P=0.036 and P=0.016, respectively). In addition, the combined expression of B7‑H2 and B7‑H3 was associated with prognostic factors, including recurrence (within 1 year) and survival rate (within 2 years), in patients with HCC. In particular, an increased area under the curve was achieved when the combined expression of B7‑H2 and B7‑H3 was considered, compared with that for α‑fetoprotein. Taken together, these results indicated that B7‑H2‑ and/or B7‑H3‑positive expression indicates a poor clinical outcome for patients, and the combination of B7‑H2 and B7‑H3 may be a preferential prognostic biomarker in patients with HCC.

View Figures

View References

1	Pan R, Zhu M, Yu C, Lv J, Guo Y, Bian Z, Yang L, Chen Y, Hu Z, Chen Z, et al: Cancer incidence and mortality: A cohort study in China, 2008–2013. Int J Cancer. 141:1315–1323. 2017. View Article : Google Scholar : PubMed/NCBI
2	Chen WQ, Zheng RS and Zhang SW: Liver cancer incidence and mortality in China, 2009. Chin J Cancer. 32:162–169. 2013. View Article : Google Scholar : PubMed/NCBI
3	Forner A and Bruix J: Biomarkers for early diagnosis of hepatocellular carcinoma. Lancet Oncol. 13:750–751. 2012. View Article : Google Scholar : PubMed/NCBI
4	Braillon A: Hepatocellular carcinoma. Lancet. 380:469author reply 470, 471. 2012. View Article : Google Scholar : PubMed/NCBI
5	Worns MA and Galle PR: Immune oncology in hepatocellular carcinoma-hype and hope. Lancet. 389:2448–2449. 2017. View Article : Google Scholar : PubMed/NCBI
6	Xu Z, Shen J, Wang MH, Yi T, Yu Y, Zhu Y, Chen B, Chen J, Li L, Li M, et al: Comprehensive molecular profiling of the B7 family of immune-regulatory ligands in breast cancer. Oncoimmunology. 5:e12078412016. View Article : Google Scholar : PubMed/NCBI
7	Hong B, Qian Y, Zhang H, Sang YW, Cheng LF, Wang Q, Gao S, Zheng M and Yao HP: Expression of B7-H4 and hepatitis B virus X in hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol. 22:4538–4546. 2016. View Article : Google Scholar : PubMed/NCBI
8	Kang FB, Wang L, Jia HC, Li D, Li HJ, Zhang YG and Sun DX: B7-H3 promotes aggression and invasion of hepatocellular carcinoma by targeting epithelial-to-mesenchymal transition via JAK2/STAT3/Slug signaling pathway. Cancer Cell Int. 15:452015. View Article : Google Scholar : PubMed/NCBI
9	Leung J and Suh WK: The CD28-B7 Family in anti-tumor immunity: Emerging concepts in cancer immunotherapy. Immune Netw. 14:265–276. 2014. View Article : Google Scholar : PubMed/NCBI
10	Dong H, Zhu G, Tamada K and Chen L: B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med. 5:1365–1369. 1999. View Article : Google Scholar : PubMed/NCBI
11	Mao Y, Chen L, Wang F, Zhu D, Ge X, Hua D and Sun J: Cancer cell-expressed B7-H3 regulates the differentiation of tumor-associated macrophages in human colorectal carcinoma. Oncol Lett. 6177–6183. 2017.PubMed/NCBI
12	Jung HI, Jeong D, Ji S, Ahn TS, Bae SH, Chin S, Chung JC, Kim HC, Lee MS and Baek MJ: Overexpression of PD-L1 and PD-L2 is associated with poor prognosis in patients with hepatocellular carcinoma. Cancer Res Treat. 49:246–254. 2017. View Article : Google Scholar : PubMed/NCBI
13	Calderaro J, Rousseau B, Amaddeo G, Mercey M, Charpy C1, Costentin C, Luciani A, Zafrani ES, Laurent A, Azoulay D, et al: Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship with clinical and pathological features. Hepatology. 64:2038–2046. 2016. View Article : Google Scholar : PubMed/NCBI
14	Vigdorovich V, Ramagopal UA, Lazar-Molnar E, Sylvestre E, Lee JS, Hofmeyer KA, Zang X, Nathenson SG and Almo SC: Structure and T cell inhibition properties of B7 family member, B7-H3. Structure. 21:707–717. 2013. View Article : Google Scholar : PubMed/NCBI
15	Tu JF, Ding YH, Ying XH, Wu FZ, Zhou XM, Zhang DK, Zou H and Ji JS: Regulatory T cells, especially ICOS+ FOXP3+ regulatory T cells, are increased in the hepatocellular carcinoma microenvironment and predict reduced survival. Sci Rep. 6:350562016. View Article : Google Scholar : PubMed/NCBI
16	Pahwa A, Beckett K, Channual S, Tan N, Lu DS and Raman SS: Efficacy of the American association for the study of liver disease and Barcelona criteria for the diagnosis of hepatocellular carcinoma. Abdom Imaging. 39:753–760. 2014. View Article : Google Scholar : PubMed/NCBI
17	Hwang M, Jayakrishnan TT, Green DE, George B, Thomas JP, Groeschl RT, Erickson B, Pappas SG, Gamblin TC and Turaga KK: Systematic review of outcomes of patients undergoing resection for colorectal liver metastases in the setting of extra hepatic disease. Eur J Cancer. 50:1747–1757. 2014. View Article : Google Scholar : PubMed/NCBI
18	Ng KM, Yan TD, Black D, Chu FC and Morris DL: Prognostic determinants for survival after resection/ablation of a large hepatocellular carcinoma. HPB (Oxford). 11:311–320. 2009. View Article : Google Scholar : PubMed/NCBI
19	Choi GH, Han DH, Kim DH, Choi SB, Kang CM, Kim KS, Choi JS, Park YN, Park JY, Kim DY, et al: Outcome after curative resection for a huge (>or=10 cm) hepatocellular carcinoma and prognostic significance of gross tumor classification. Am J Surg. 198:693–701. 2009. View Article : Google Scholar : PubMed/NCBI
20	Lee SG, Hwang S, Jung JP, Lee YJ, Kim KH and Ahn CS: Outcome of patients with huge hepatocellular carcinoma after primary resection and treatment of recurrent lesions. Br J Surg. 94:320–326. 2007. View Article : Google Scholar : PubMed/NCBI
21	Liu Y, Wang YR, Dingi GH, Yang TS, Jiang SL, Wang L, Xun LJ, Song RM, Song ZS and Zhou B: Influence of surgical resection of hepatocellular carcinoma(HCC) for hematogenous dissemination of HCC cells and its effect on recurrence and metastasis: 3 years prospective study. Neoplasma. 62:635–640. 2015. View Article : Google Scholar : PubMed/NCBI
22	Xu B, Cai Z, Zeng Y, Chen L, Du X, Huang A, Liu X and Liu J: Alpha-Methylacyl-CoA racemase (AMACR) serves as a prognostic biomarker for the early recurrence/metastasis of HCC. J Clin Pathol. 67:974–979. 2014. View Article : Google Scholar : PubMed/NCBI
23	Jiang YF, Yang ZH and Hu JQ: Recurrence or metastasis of HCC: Predictors, early detection and experimental antiangiogenic therapy. World J Gastroenterol. 6:61–65. 2000. View Article : Google Scholar : PubMed/NCBI
24	Kang TW, Yevsa T, Woller N, Hoenicke L, Wuestefeld T, Dauch D, Hohmeyer A, Gereke M, Rudalska R, Potapova A, et al: Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature. 479:547–551. 2011. View Article : Google Scholar : PubMed/NCBI
25	Petruzziello A: Epidemiology of hepatitis B virus (HBV) and hepatitis C virus (HCV) related hepatocellular carcinoma. Open Virol J. 12:26–32. 2018. View Article : Google Scholar : PubMed/NCBI
26	Liu CJ and Kao JH: Hepatitis B virus-related hepatocellular carcinoma: Epidemiology and pathogenic role of viral factors. J Chin Med Assoc. 70:141–145. 2007. View Article : Google Scholar : PubMed/NCBI
27	Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC and Roudot-Thorav F: The burden of liver disease in Europe: A review of available epidemiological data. J Hepatol. 58:593–608. 2013. View Article : Google Scholar : PubMed/NCBI
28	Sumie S, Kawaguchi T, Komuta M, Kuromatsu R, Itano S, Okuda K, Taniguchi E, Ando E, Takata A, Fukushima N, et al: Significance of glucose intolerance and SHIP2 expression in hepatocellular carcinoma patients with HCV infection. Oncol Rep. 18:545–552. 2007.PubMed/NCBI
29	Kawaguchi T, Nakano D, Okamura S, Shimose S, Hayakawa M, Niizeki T, Koga H and Torimura T: Spontaneous regression of hepatocellular carcinoma with reduction in angiogenesis-related cytokines after treatment with sodium-glucose cotransporter 2 inhibitor in a cirrhotic patient with diabetes mellitus. Hepatol Res. 2018 Sep;4.Doi: 10.1111/hepr.13247.
30	Chen L, Xie Q, Wang Z, Shi L, Wu C and Jiang J: Assessment of combined expression of B7-H3 and B7-H4 as prognostic marker in esophageal cancer patients. Oncotarget. 7:77237–77243. 2016.PubMed/NCBI
31	Burris HA, Callahan MK, Tolcher AW, Kummar S, Falchook GS, Pachynski RK, Tykodi SS, Gibney GT, Seiwert TY, Gainor JF, et al: Phase 1 safety of ICOS agonist antibody JTX-2011 alone and with nivolumab (nivo) in advanced solid tumors; predicted vs. observed pharmacokinetics (PK) in ICONIC. J Clin Oncol. 15:3033. 2017. View Article : Google Scholar